New Formulations of Anticancer Drugs for Targeted Treatment of Triple Negative Breast Cancers
Prof S Linardopoulos
Prof A Porter
Friday, November 22, 2019
Funded PhD Project (European/UK Students Only)
Understanding systems and molecular mechanisms underlying cancer immunotherapy for the development of precision immunotherapy with informed strategies
Triple negative breast cancer accounts for approximately 15% of breast cancers and, once metastatic, is incurable. The ICR are developing preclinical drugs that can regress triple negative breast cancer tumours and although this approach is very promising, concerns remain about the drugs’ systemic side-effects, such as neutropenia, due to the nature of the target. With this PhD studentship, the student will develop a targeted nanoparticle system that delivers these drugs directly to the triple negative breast cancer cells to increase their potency and reduce side effects. The nanomaterials will also be designed so that they can be imaged deep inside the breast cancers using new ultrabright fluorescent-based imaging techniques.
Within this PhD studentship, the student will be trained in state-of-the-art nanomaterials synthesis and characterisation techniques to design and optimise the nanomaterials delivery/imaging technology using facilities within Dr. Xie and Prof. Porter’s group in the Dept. Materials, Faculty of Engineering. The student will work on identifying targets to the cancers with Dr. Robert Krypta (Division of Cancer and Surgery, Imperial). At the ICR the student will perform cell-based assays and in vivo efficacy studies in the already established models in laboratory of Target Discovery and Apoptosis. The multidisciplinary team of supervisors will train an ambitious and pro-active student towards the goal of treating more aggressive breast cancers and avoiding unwanted systemic side effects of the new chemotherapy. This project, funded by the ICR-CRUK-Imperial convergence science PhD scheme will enable a graduate with an excellent honour’s degree in Chemistry, Pharmacy or Chemical Engineering to undertake a 4 year training programme. The program includes a PhD dissertation plus training in related research topics (cancer, imaging and nanomaterials) and transferable key skills, leading to the submission of a doctoral thesis and the award of a PhD.
2. Drug formulation
3. Breast cancer
Convergence Science PhDs cover tuition fees for UK/EU students only